Prostate Specific Antigen Screening on a Nationwide Level : Featuring the Contribution of Race and Life Expectancy in Decision Making
Copyright © 2023 Elsevier Inc. All rights reserved..
BACKGROUND: Estimation of life expectancy (LE) is important for the relative benefit of prostate specific antigen (PSA) screening. Limited data exists regarding screening for Black men with extended LE. The aim of the current study was to assess temporal trends in screening in United States (US) Black men with limited vs. extended LE, using a nationally representative dataset.
MATERIALS AND METHODS: Using the National Health Institution Survey (NHIS) 2000 to 2018, men aged ≥40 without prior history of prostate cancer (PCa) who underwent PSA screening in the last 12 months were stratified into limited LE (ie, LE <15 years) and extended LE (ie, LE≥15 years) using the validated Schonberg index. LE-stratified temporal trends in PSA screening were analyzed for all men, and then in Black men. Weighted multivariable analyses and dominance analyses identified the predictors of PSA screening.
RESULTS: PSA screening declined over the study period both for all eligible men with limited and extended LE, particularly between NHIS 2008 and 2013 (27.9%-20.7% in the extended). Screening increased significantly in Black men with extended LE (17.6% in 2010-25.7% in 2018). However, LE was not an independent predictor of screening in the Black cohort. Prior recipient of colonoscopy (55%-57%) and visit to health care provider (24%-32%) were the most important determinants for screening.
CONCLUSION: For US men with extended LE, only 1 in 4 receive PSA screening, with a decline over the study-period. Screening rates increased for Black men. However, these changes were not driven by LE consideration itself, but participation in other screenings and access to a provider.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical genitourinary cancer - 22(2024), 2 vom: 01. Apr., Seite 269-280.e2 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dalela, Deepansh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Black |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clgc.2023.11.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367237954 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367237954 | ||
| 003 | DE-627 | ||
| 005 | 20240410232417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clgc.2023.11.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM367237954 | ||
| 035 | |a (NLM)38233279 | ||
| 035 | |a (PII)S1558-7673(23)00255-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dalela, Deepansh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prostate Specific Antigen Screening on a Nationwide Level |b Featuring the Contribution of Race and Life Expectancy in Decision Making |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Estimation of life expectancy (LE) is important for the relative benefit of prostate specific antigen (PSA) screening. Limited data exists regarding screening for Black men with extended LE. The aim of the current study was to assess temporal trends in screening in United States (US) Black men with limited vs. extended LE, using a nationally representative dataset | ||
| 520 | |a MATERIALS AND METHODS: Using the National Health Institution Survey (NHIS) 2000 to 2018, men aged ≥40 without prior history of prostate cancer (PCa) who underwent PSA screening in the last 12 months were stratified into limited LE (ie, LE <15 years) and extended LE (ie, LE≥15 years) using the validated Schonberg index. LE-stratified temporal trends in PSA screening were analyzed for all men, and then in Black men. Weighted multivariable analyses and dominance analyses identified the predictors of PSA screening | ||
| 520 | |a RESULTS: PSA screening declined over the study period both for all eligible men with limited and extended LE, particularly between NHIS 2008 and 2013 (27.9%-20.7% in the extended). Screening increased significantly in Black men with extended LE (17.6% in 2010-25.7% in 2018). However, LE was not an independent predictor of screening in the Black cohort. Prior recipient of colonoscopy (55%-57%) and visit to health care provider (24%-32%) were the most important determinants for screening | ||
| 520 | |a CONCLUSION: For US men with extended LE, only 1 in 4 receive PSA screening, with a decline over the study-period. Screening rates increased for Black men. However, these changes were not driven by LE consideration itself, but participation in other screenings and access to a provider | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Black | |
| 650 | 4 | |a PSA | |
| 650 | 4 | |a Prevention | |
| 650 | 4 | |a Schonberg Index | |
| 650 | 4 | |a Surveillance | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 700 | 1 | |a Corsi, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Bronkema, Chandler |e verfasserin |4 aut | |
| 700 | 1 | |a Sood, Akshay |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Sohrab |e verfasserin |4 aut | |
| 700 | 1 | |a Majdalany, Sami E |e verfasserin |4 aut | |
| 700 | 1 | |a Butaney, Mohit |e verfasserin |4 aut | |
| 700 | 1 | |a Jamil, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Palma-Zamora, Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Rakic, Nikola |e verfasserin |4 aut | |
| 700 | 1 | |a Kovacevic, Natalija |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Wooju |e verfasserin |4 aut | |
| 700 | 1 | |a Menon, Mani |e verfasserin |4 aut | |
| 700 | 1 | |a Rogers, Craig G |e verfasserin |4 aut | |
| 700 | 1 | |a Schonberg, Mara A |e verfasserin |4 aut | |
| 700 | 1 | |a Abdollah, Firas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical genitourinary cancer |d 2005 |g 22(2024), 2 vom: 01. Apr., Seite 269-280.e2 |w (DE-627)NLM160229936 |x 1938-0682 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:2 |g day:01 |g month:04 |g pages:269-280.e2 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clgc.2023.11.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 2 |b 01 |c 04 |h 269-280.e2 | ||